The Latest
-
Will medtech M&A pick back up in the second half?
The year kicked off with a handful of acquisitions from top companies. Dealmaking has since slowed amid economic uncertainty but could be poised for a rebound.
-
Trump tariffs
US plans 30% tariffs on EU, Mexico
President Donald Trump unveiled the new duty rates, set to begin Aug. 1, in separate letters shared on social media Saturday morning.
-
Q&A
Amazon’s Rowland Illing talks about AI’s shifting focus in medtech
Amazon Web Services’ global chief medical officer said the healthcare industry is seeing an “absolute explosion” of generative AI use cases, with large models that can be adapted to a variety of tasks.
-
Abbott gains national CMS coverage for tricuspid valve repair
The agency’s decision supports broader access to a minimally invasive treatment for patients with severe tricuspid regurgitation, in which blood can leak backward into the heart.
-
Trump tariffs
US plans 35% tariffs on Canada imports
President Donald Trump said the duties will take effect Aug. 1 while decrying the country’s retaliatory levies to U.S. tariffs.
-
Neuros raises $56M to commercialize nerve stimulation system for post-amputation pain
Patients with Altius implants had fewer mean pain days per week, used opioids less and scored higher on a quality-of-life scale in a clinical trial.
-
Samsung to acquire digital health firm Xealth
The purchase of the Providence spinoff bolsters Samsung’s push to unify health data, including through wearables like the electronics giant’s Galaxy Watch line.
-
Medtronic names CFO for diabetes spinoff
The company named Chad Spooner CFO of MiniMed ahead of plans to spin out the diabetes unit into a separate public firm.
-
BD appoints Bilal Muhsin as president of new connected care group
The former Masimo executive will lead strategy development to support the transition to BD’s revised business structure over the next several months.
-
Implantable glucose monitor competitor emerges with early data
Glucotrack, which is developing a glucose monitor that is implanted through a minimally invasive surgery, said the small study met safety and performance goals.
-
Boston Scientific gets expanded PFA label for persistent AFib
Patients whose atrial fibrillation lasts longer than seven days and who do not respond well to drug therapy are now eligible for treatment with the Farapulse pulsed field ablation system.